Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides
Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides.
Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
Company Details
- Employees
- 24
- Founded
- -
- Address
- Austin, Texas, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://maxwellbiosciences.com/
- Keywords
- Ikeja.
- HQ
- Austin, Texas
Maxwell Biosciences Questions
Maxwell Biosciences's website is https://maxwellbiosciences.com/
Maxwell Biosciences's LinkedIn profile is https://www.linkedin.com/company/maxwell-biosciences
Maxwell Biosciences has
24 employees.
View email and phone details for 24
employees at Maxwell Biosciences.
Maxwell Biosciences's industry is
Biotechnology Research
Maxwell Biosciences's top competitors are
Molecule Ai,
Rani Therapeutics,
Microba Life Sciences,
Onepipe,
Lumos Pharma,
Aminex Therapeutics,
Genprex, Inc.,
Elios Therapeutics, Llc,
Plus Therapeutics, Inc.,
Curtana Pharmaceuticals.
Maxwell Biosciences's categories are Biotechnology Research
Maxwell Biosciences's founding year is 2016
